Dr. Zarrabi on the Real-World Data With Axitinib/Pembrolizumab Vs Ipilimumab/Nivolumab in Clear Cell RCC

Video

In Partnership With:

Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.

Kevin Zarrabi, MD, second-year hematology/oncology fellow, Fox Chase Cancer Center, discusses an analysis of real-world outcomes with axitinib (Inlyta) plus pembrolizumab (Keytruda) vs ipilimumab (Yervoy) plus nivolumab (Opdivo) in patients with metastatic clear cell renal cell carcinoma (RCC). 

Results demonstrated similar progression-free survival (PFS) and overall survival (OS) rates in patients with intermediate- or poor-risk disease, regardless of which combination they received, according to Zarrabi. These data are valuable, as they provide evidence that benefit can be derived with either regimen in the real-world setting, Zarrabi explains.

Additionally, although the PFS and OS data were similar between the 2 combination regimens, the results were not consistent with what had previously been observed on the clinical trials, Zarrabi adds. Updated data from both the phase 3 KEYNOTE-426 (NCT02853331) and the phase 3 CheckMate-214 trials (NCT02231749) showed a sustained survival benefit; however, real-world data showed a survival benefit that was not as significant as what was reported in the trial population, Zarrabi concludes.

Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael J. Overman, MD
Jason Efstathiou, MD, DPhil
Amin Nassar, MD
Haeseong Park, MD, MPH
Matthew P. Goetz, MD
Phillip J. Koo, MD
Daniel Petrylak, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center